@article{3087568,
    title = "MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy",
    author = "Lalla, R.V. and Bowen, J. and Barasch, A. and Elting, L. and Epstein, J. and Keefe, D.M. and McGuire, D.B. and Migliorati, C. and Nicolatou-Galitis, O. and Peterson, D.E. and Raber-Durlacher, J.E. and Sonis, S.T. and Elad, S. and The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASC/ISOO) and Al-Dasooqi, N. and Brennan, M. and Gibson, R. and Fulton, J. and Hewson, I. and Jensen, S.B. and Logan, R. and Öhrn, K.E.O. and Sarri, T. and Saunders, D. and von Bültzingslöwen, I. and Yarom, N. and Allemano, J. and Al-Azri, A.R. and Antunes, H.S. and Ariyawardana, A. and Bateman, E. and Blijlevens, N. and Boers-Doets, C.B. and Bossi, P. and Brown, C.G. and Chang, Y.-C. and Cheng, K.K. and Cooksley, C. and Correa, E.P. and Dennis, K. and Di Palma, M. and Drucker, S. and Eilers, J. and Escalante, C. and Estilo, C.L. and Everaus, H. and Fijlstra, M. and Fliedner, M. and Freidank, A. and Gerber, E. and Gibson, F. and Gomez, J.G. and Halm, J. and Hita, G. and Hutchins, R.D. and Hodgson, B. and Hovan, A. and Jarvis, V. and King, E.E. and Kouloulias, V.E. and Latortue, M.C. and Lees, J. and Lopes, N.N.F. and Loprinzi, C. and Michelet, M. and Mori, T. and Nair, R.G. and Niscola, P. and Oberle-Edwards, L.K. and Osaguona, A. and Parelkar, P. and Park, J. and Parker, I. and Pettersson, B.G. and Potting, C. and Rao, N.G. and Riesenbeck, D. and Rouleau, T. and Schubert, M.M. and Silverman, S., Jr. and Soga, Y. and Spijkervet, F.K.L. and Stokman, M. and Stringer, A.M. and Tissing, W.J.E. and van der Velden, W.J.F.M. and van de Wetering, M.D. and Vithala, M. and Weikel, D.S. and Yazbeck, R. and Yeoh, E. and Zadik, Y.",
    journal = "JMIR Cancer",
    year = "2014",
    volume = "120",
    number = "10",
    pages = "1453-1461",
    publisher = "John Wiley and Sons Inc",
    doi = "10.1002/cncr.28592",
    keywords = "acetylsalicylic acid;  amifostine;  benzydamine;  chlorhexidine;  doxepin;  glutamine;  granulocyte colony stimulating factor;  granulocyte macrophage colony stimulating factor;  iseganan;  misoprostol;  morphine;  octreotide;  palifermin;  pentoxifylline;  pilocarpine;  probiotic agent;  salazosulfapyridine;  sucralfate;  zinc sulfate, cancer chemotherapy;  cancer radiotherapy;  cancer therapy;  cryotherapy;  diet supplementation;  gastrointestinal mucositis;  head and neck cancer;  health care policy;  human;  hyperbaric oxygen;  low level laser therapy;  lozenge;  mouth cavity;  mouth hygiene;  mucosa inflammation;  oral mucositis;  patient controlled analgesia;  phototherapy;  practice guideline;  priority journal;  review;  systematic review;  whole body radiation, gastrointestinal;  guidelines;  mucositis;  Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO);  oral;  stomatitis, Amifostine;  Analgesics;  Anti-Infective Agents;  Anti-Inflammatory Agents;  Anti-Ulcer Agents;  Antineoplastic Agents;  Cryotherapy;  Cytokines;  Esophagitis;  Evidence-Based Medicine;  Humans;  Hyperbaric Oxygenation;  Intercellular Signaling Peptides and Proteins;  Laser Therapy, Low-Level;  Mucositis;  Neoplasms;  Oral Hygiene;  Phototherapy;  Proctitis;  Protective Agents;  Radiation-Protective Agents;  Radiotherapy;  Stomatitis;  Sucralfate",
    abstract = "BACKGROUND Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for mucositis. METHODS A literature search was conducted to identify eligible published articles, based on predefined inclusion/exclusion criteria. Each article was independently reviewed by 2 reviewers. Studies were rated according to the presence of major and minor flaws as per previously published criteria. The body of evidence for each intervention, in each treatment setting, was assigned a level of evidence, based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. RESULTS The literature search identified 8279 papers, 1032 of which were retrieved for detailed evaluation based on titles and abstracts. Of these, 570 qualified for final inclusion in the systematic reviews. Sixteen new guidelines were developed for or against the use of various interventions in specific treatment settings. In total, the MASCC/ISOO Mucositis Guidelines now include 32 guidelines: 22 for oral mucositis and 10 for gastrointestinal mucositis. This article describes these updated guidelines. CONCLUSIONS The updated MASCC/ISOO Clinical Practice Guidelines for mucositis will help clinicians provide evidence-based management of mucositis secondary to cancer therapy. © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society."
}